{{Rsnum
|rsid=523349
|Gene=SRD5A2
|Chromosome=2
|position=31580636
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=G
|GMAF=0.3425
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
|Gene_s=SRD5A2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 64.6 | 32.3 | 3.1
| HCB | 31.1 | 42.2 | 26.7
| JPT | 39.5 | 48.8 | 11.6
| YRI | 58.7 | 38.1 | 3.2
| ASW | 0.0 | 0.0 | 0.0
| CHB | 31.1 | 42.2 | 26.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}
[[rs523349]] is a SNP in the steroid-5-alpha-reductase [[SRD5A2]] gene; it is also known as V89L.

In a study of a total of 1,466 Caucasian cases of [[ovarian cancer]], the [[rs523349]](G) allele showed a significant trend of increasing risk of [[ovarian cancer]] per rare allele (p = 0.00002).{{PMID|18086758|OA=1
}}

{{ neighbor
| rsid = 9282858
| distance = 120
}}

{{PMID|18431743|OA=1
}}  showed '''no association''' with ovarian cancer risk 4,624 invasive epithelial ovarian cancer cases and 8,113 controls of white non-Hispanic origin [[ovarian cancer]]

{{PMID Auto
|PMID=19926884
|Title=Analysis of Polymorphisms in the SRD5A2 Gene and Semen Parameters in Estonian Men
}}

{{PMID Auto
|PMID=19914946
|Title=Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review
}}

{{PMID Auto
|PMID=20855474
|Title=Association of Steroid 5{alpha} Reductase Type II Variants and Serum Androstane-3{alpha},17{beta}-Diol Glucuronide Concentration in Chinese Elderly Men
}}

{{PMID Auto
|PMID=21715084
|Title=SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy
}}

{{PMID Auto
|PMID=22735779
|Title=Variants in the SRD5A2 gene are associated with quality of semen
}}

{{ClinVar
|rsid=523349
|Reversed=0
|FwdREF=G
|FwdALT=C
|REF=G
|ALT=C
|RSPOS=31805706
|CHROM=2
|GMAF=0.3425
|dbSNPBuildID=83
|SSR=0
|SAO=0
|VP=0x05016800000017011f100101
|GENEINFO=SRD5A2:6716
|GENE_NAME=SRD5A2
|GENE_ID=6716
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000002.11:g.31805706G>C
|CLNSIG=1
|Tags=PM;PMC;SLO;VLD;G5A;G5;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD
|CAF=0.3425; 0.6575
|COMMON=1
|CLNACC=RCV000083650.1
|CLNDBN=not provided
|Disease=not provided
}}

{{PMID Auto
|PMID=18163429
|Title=Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
|OA=1
}}

{{PMID Auto
|PMID=18603647
|Title=Functional genetic polymorphisms and female reproductive disorders: Part I: Polycystic ovary syndrome and ovarian response.
|OA=1
}}

{{PMID Auto
|PMID=19168589
|Title=Variants in hormone-related genes and the risk of biliary tract cancers and stones: a population-based study in China.
|OA=1
}}

{{PMID Auto
|PMID=20215396
|Title=Genetics of hypospadias: are single-nucleotide polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 really associated with the malformation?
}}

{{PMID Auto
|PMID=21530059
|Title=Association of genetic variants in the two isoforms of 5alpha-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome.
}}

{{GET Evidence
|gene=SRD5A2
|aa_change=Leu88Val
|aa_change_short=L88V
|impact=not reviewed
|qualified_impact=Insufficiently evaluated not reviewed
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs523349
|overall_frequency_n=7205
|overall_frequency_d=9934
|overall_frequency=0.725287
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=67
|n_articles=0
|n_articles_annotated=0
|gene_in_genetests=Y
|genetests_testable=Y
|nblosum100=0
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23091730
|Title=Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men
|OA=1
}}

{{PMID Auto
|PMID=23505265
|Title=Sex dependent influence of a functional polymorphism in steroid 5-α-reductase type 2 (SRD5A2) on post-traumatic stress symptoms
|OA=1
}}

{{PMID Auto
|PMID=23499746
|Title=SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
}}

{{PMID Auto
|PMID=22901566
|Title=Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis.
}}

{{PMID Auto
|PMID=23088992
|Title=Exploration of gene-environment interactions, maternal effects and parent of origin effects in the etiology of hypospadias.
|OA=1
}}

{{PMID Auto
|PMID=23867117
|Title=Associations between polymorphisms in sex steroid related genes and autistic-like traits
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}